MacroGenics to price IPO of 5 million shares at $16.00 per share

BofA Merrill Lynch, Leerink Swann and Stifel are joint bookrunners

By Devika Patel

Knoxville, Tenn., Oct. 9 - MacroGenics, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The deal was announced Sept. 4.

The price per share is expected to be $16.00.

BofA Merrill Lynch, Leerink Swann and Stifel are the joint bookrunning managers. Lazard Capital Markets and Wedbush PacGrow Life Sciences are the co-managers.

Proceeds will be used for clinical development of margetuximab and MGA271, research and development to advance other product candidates and working capital and general corporate purposes, which may include in-licensing or acquiring other products or technologies.

The biopharmaceutical company is based in Rockville, Md. It intends to list its common stock on the Nasdaq under the symbol "MGNX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.